AWAK Technologies (AWAK), a pioneering medical technology company developing a wearable dialysis product and other complementary solutions for chronic kidney disease (CKD) management, today announced that its kidney disease progression prediction (KDPP) Artificial Intelligence (AI) model for CKD patient care has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). The KDPP model helps to assess the risk of kidney disease progression and initiation of renal
AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia The Series B round was co-led by new investor Lion X Ventures and long-term investor.
SINGAPORE - Temasek Holdings is exploring selling Advanced MedTech, multiple sources told Reuters on Monday (Nov 14), after the medical devices firm, fully-owned by the Singaporean state investor, received interest from suitors including buyout funds. Two investment banks have been tapped to launch a sale process for Singapore-headquartered MedTech, which could be valued at roughly $1 billion (S$1.4 billion), two.